The company published results from nine clinical trials of 900 patients that compared cumulative pain scores, opioid consumption and occurrence of opioid-related adverse events after administrating either EXPAREL or bupivacaine HCI.
EXPAREL also produced longer time to first opioid rescues and decreased opioid requirements and incidences of ORAEs. Thirty-six percent of bupivacaine HCI patients experienced at least one ORAE compared to 20 percent of EXPAREL patients.
More Articles on Anesthesia:
Nerve Blocks May Be Safer Form of Anesthesia
NorthBay Healthcare Purchases Brain Oxygen Monitoring Device for Anesthesiologists
New Hardship Exception for Anesthesiologists to Avoid the EHR Penalty
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
